Prima BioMed (NASDAQ:IMMP) Stock Passes Below 50 Day Moving Average – Here’s What Happened

Prima BioMed Ltd (NASDAQ:IMMP)’s share price passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.44 and traded as low as $0.37. Prima BioMed shares last traded at $0.3766, with a volume of 581,594 shares changing hands.

More Prima BioMed News

Here are the key news stories impacting Prima BioMed this week:

• Positive Sentiment: Immutep said it will present positive interim Phase I data for IMP761, its first-in-class LAG-3 agonist antibody, at the EULAR 2026 conference, which could support the long-term pipeline story. Article Title
• Neutral Sentiment: Several law firms, including Rosen, Robbins LLP, Schall, DJS, Pomerantz, Bernstein Liebhard, and others, issued investor alerts and deadline reminders tied to an existing securities class action involving IMMP purchasers from March 24, 2025 to March 12, 2026. Article Title
• Neutral Sentiment: The lawsuit filings allege Immutep misled investors about the viability and efficacy of a drug candidate, with a lead-plaintiff deadline set for July 6, 2026. Article Title
• Negative Sentiment: One lawsuit notice described the case as stemming from an alleged “83% stock collapse,” reinforcing concerns that the company faces meaningful legal and reputational overhang. Article Title

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Maxim Group cut Prima BioMed from a “buy” rating to a “hold” rating in a research report on Friday, March 13th. Citizens Jmp cut Prima BioMed from an “outperform” rating to a “market perform” rating in a research report on Friday, March 13th. Wall Street Zen raised Prima BioMed to a “hold” rating in a research report on Saturday, April 18th. Finally, Robert W. Baird cut Prima BioMed from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $7.00 to $1.00 in a research report on Friday, March 13th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $5.50.

Prima BioMed Trading Down 3.1%

The company’s fifty day moving average price is $0.44 and its 200-day moving average price is $1.73.

Hedge Funds Weigh In On Prima BioMed

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC grew its holdings in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.32% of the company’s stock.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.